141 related articles for article (PubMed ID: 37923571)
1. Pharmacokinetics and Therapeutic Target Attainment of Meropenem in Pediatric Post-Liver Transplant Patients: Extended vs Intermittent Infusion.
Morales Junior R; Juodinis VD; Telles JP; Romano P; Duarte NJC; De Souza DC; Santos SRCJ
Transplant Proc; 2023 Dec; 55(10):2456-2461. PubMed ID: 37923571
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Target Attainment of 3-Hour Extended Infusion of Meropenem in Patients With Septic Burns.
Messiano CG; Morales Junior R; Pereira GO; Silva Junior EMD; Gomez DS; Santos SRCJ
Clin Ther; 2022 Apr; 44(4):624-629. PubMed ID: 35260257
[TBL] [Abstract][Full Text] [Related]
3. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
4. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
[TBL] [Abstract][Full Text] [Related]
8. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
[TBL] [Abstract][Full Text] [Related]
10. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.
Pea F; Viale P; Cojutti P; Furlanut M
Antimicrob Agents Chemother; 2012 Dec; 56(12):6343-8. PubMed ID: 23045356
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
12. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of meropenem in critically ill patients with severe infections.
Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
[TBL] [Abstract][Full Text] [Related]
14. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
[TBL] [Abstract][Full Text] [Related]
15. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection.
Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C
J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867
[TBL] [Abstract][Full Text] [Related]
18. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
Bo SN; Li HL; Zhu X; Yao GQ; Hu YF; Zhai SD; Lu W; Wang SY; Xu YZ; He B
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):145-8. PubMed ID: 22401158
[TBL] [Abstract][Full Text] [Related]
20. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
